


Mirodenafil

Chemical Properties

CAS No. :	862189-95-5
Formula:	C ₂₆ H ₃₇ N ₅ O ₅ S
Molecular Weight:	531.67
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.
Targets(IC50)	Apoptosis,Glucocorticoid Receptor,PDE,Wnt/beta-catenin
In vitro	The pharmacokinetics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities [1]. Mirodenafil administered with alcohol had a tolerability profile comparable to that of mirodenafil alone [2]. The concurrent administration of mirodenafil with alcohol was not associated with clinically significant hemodynamic changes in these healthy male volunteers in Korea. The coadministration of ketoconazole and rifampicin resulted in significant changes in systemic exposure to mirodenafil, in these healthy Korean male volunteers [3].

Solubility Information

Solubility	DMSO: 27.5 mg/mL (51.72 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8809 mL	9.4043 mL	18.8087 mL
5 mM	0.3762 mL	1.8809 mL	3.7617 mL
10 mM	0.1881 mL	0.9404 mL	1.8809 mL
50 mM	0.0376 mL	0.1881 mL	0.3762 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Paick, J.S., et al., Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. *J Sex Med*, 2008. 5(11): p. 2672-80.

Kim, B.H., et al., Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. *Clin Ther*, 2009. 31(6): p. 1234-43.

Shin, K.H., et al., The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. *Clin Ther*, 2009. 31(12): p. 3009-20.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481